4,259 results on '"Choi, So"'
Search Results
2. PBPK modeling to predict the pharmacokinetics of venlafaxine and its active metabolite in different CYP2D6 genotypes and drug–drug interactions with clarithromycin and paroxetine
3. Physiologically based pharmacokinetic (PBPK) modeling of pitavastatin in relation to SLCO1B1 genetic polymorphism
4. PBPK modeling to predict the pharmacokinetics of pantoprazole in different CYP2C19 genotypes
5. The PIN1-YTHDF1 axis promotes breast tumorigenesis via the m6A-dependent stabilization of AURKA mRNA
6. Role of monocarboxylate transporter I/lactate dehydrogenase B-mediated lactate recycling in tamoxifen-resistant breast cancer cells
7. Physiologically based pharmacokinetic (PBPK) modeling to predict the pharmacokinetics of irbesartan in different CYP2C9 genotypes
8. Effects of CYP2C9 and CYP2C19 genetic polymorphisms on the pharmacokinetics and pharmacodynamics of gliclazide in healthy subjects
9. Naringin promotes fat browning mediated by UCP1 activation via the AMPK signaling pathway in 3T3-L1 adipocytes
10. Distinctive role of inflammation in tissue repair and regeneration
11. MEKs/ERKs-mediated FBXO1/E2Fs interaction interference modulates G1/S cell cycle transition and cancer cell proliferation
12. Effects of CYP2D6*10 allele on the pharmacokinetics of tolperisone
13. New insights into the role of the Golgi apparatus in the pathogenesis and therapeutics of human diseases
14. Enhanced bioavailability and hepatoprotective effect of silymarin by preparing silymarin-loaded solid dispersion formulation using freeze-drying method
15. Physiologically based pharmacokinetic (PBPK) modeling of flurbiprofen in different CYP2C9 genotypes
16. Kaempferol sensitizes cell proliferation inhibition in oxaliplatin-resistant colon cancer cells
17. Physiologically based pharmacokinetic modelling to predict the pharmacokinetics of metoprolol in different CYP2D6 genotypes
18. Trehalose ameliorates prodromal non-motor deficits and aberrant protein accumulation in a rotenone-induced mouse model of Parkinson’s disease
19. Physiologically based pharmacokinetic (PBPK) modeling of piroxicam with regard to CYP2C9 genetic polymorphism
20. Adapalene induces adipose browning through the RARβ-p38 MAPK-ATF2 pathway
21. Anti-angiogenesis revisited: reshaping the treatment landscape of advanced non-small cell lung cancer
22. Structure–activity relationships of novel quinazoline derivatives with high selectivity for HER2 over EGFR
23. The effects of BRL-50481 on ovalbumin-induced asthmatic lung inflammation exacerbated by co-exposure to Asian sand dust in the murine model
24. Physiologically based pharmacokinetic modeling of candesartan related to CYP2C9 genetic polymorphism in adult and pediatric patients
25. Understanding of sarcopenia: from definition to therapeutic strategies
26. Amyloidogenic, neuroinflammatory and memory dysfunction effects of HIV-1 gp120
27. Recent advances in the pathology of prodromal non-motor symptoms olfactory deficit and depression in Parkinson’s disease: clues to early diagnosis and effective treatment
28. Triamterene induces autophagic degradation of lysosome by exacerbating lysosomal integrity
29. Peroxisome proliferator-activated receptor gamma: a novel therapeutic target for cognitive impairment and mood disorders that functions via the regulation of adult neurogenesis
30. Ginkwanghols A and B, osteogenic coumaric acid-aliphatic alcohol hybrids from the leaves of Ginkgo biloba
31. The role of mucosal barriers in human gut health
32. The multifaceted role of NRF2 in cancer progression and cancer stem cells maintenance
33. Treatments of inflammatory bowel disease toward personalized medicine
34. Hyperthermal paclitaxel-bound albumin nanoparticles co-loaded with indocyanine green and hyaluronidase for treating pancreatic cancers
35. Overview of COVID-19 inflammatory pathogenesis from the therapeutic perspective
36. PBPK modeling to predict the pharmacokinetics of pantoprazole in different CYP2C19 genotypes
37. The PIN1-YTHDF1 axis promotes breast tumorigenesis via the m6A-dependent stabilization of AURKA mRNA
38. Pharmacokinetics of ginsenosides following repeated oral administration of red ginseng extract significantly differ between species of experimental animals
39. Effects of CYP2D6 genetic polymorphism on the pharmacokinetics of metoclopramide
40. ABCB1 c.2677G>T/c.3435C>T diplotype increases the early-phase oral absorption of losartan
41. Brain energy metabolism and multiple sclerosis: progress and prospects
42. Inhibition of PTP1B by farnesylated 2-arylbenzofurans isolated from Morus alba root bark: unraveling the mechanism of inhibition based on in vitro and in silico studies
43. Evaluation and live monitoring of pH-responsive HSA-ZnO nanoparticles using a lung-on-a-chip model
44. NRF2-driven redox metabolism takes center stage in cancer metabolism from an outside-in perspective
45. Trichothecene and tremulane sesquiterpenes from a hallucinogenic mushroom Gymnopilus junonius and their cytotoxicity
46. Chemical constituents from the roots of Kadsura coccinea with their protein tyrosine phosphatase 1B and acetylcholinesterase inhibitory activities
47. Interactions of ginseng with therapeutic drugs
48. Effects of CYP2C9 and CYP2C19 genetic polymorphisms on the pharmacokinetics and pharmacodynamics of gliclazide in healthy subjects
49. The PIN1-YTHDF1 axis promotes breast tumorigenesis via the m6A-dependent stabilization of AURKA mRNA.
50. Naringin promotes fat browning mediated by UCP1 activation via the AMPK signaling pathway in 3T3-L1 adipocytes
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.